Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | BLVRB | P30043 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1498095 | 0.88 | TSHR (0.61) | TSHRCASP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1498097 | 0.88 | TSHR (0.61) | TSHRCASP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11062287 | 0.81 | GLO1 (0.48) | MEN1KMT2AMAPTCYP2C19HTT | |
| SCHEMBL11062285 | 0.81 | GLO1 (0.48) | MEN1KMT2AMAPTCYP2C19HTT | |
| SCHEMBL28234558 | 0.77 | MEN1 (0.55) | SMN1; SMN2MEN1KMT2AMAPTCYP2C19 | |
| SCHEMBL7870702 | 0.76 | HTR3E (0.58) | TSHRMEN1KMT2AMAPTCYP2C19 | |
| SCHEMBL30102029 | 0.76 | HTR3E (0.58) | TSHRMEN1KMT2AMAPTCYP2C19 | |
| SCHEMBL7870699 | 0.76 | HTR3E (0.58) | TSHRMEN1KMT2AMAPTCYP2C19 | |
| SCHEMBL111279 | 0.74 | TSHR (1.00) | TSHRCASP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3396994 | 0.73 | TSHR (0.52) | TSHRCASP1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220142889-A1 | TOPICAL COMPOSITION | FRAMERGY INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220023829-A1 | AMORPHOUS METAL ORGANIC FRAMEWORKS AND METHODS OF PREPARING THE SAME | ABSORPTION SOLUTIONS LLC | 2022-01-27 | — | — | US | disclosed |
| EP-3890878-A2 | AMORPHOUS METAL ORGANIC FRAMEWORKS AND METHODS OF PREPARING THE SAME | Framergy Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117833-A2 | AMORPHOUS METAL ORGANIC FRAMEWORKS AND METHODS OF PREPARING THE SAME | FRAMERGY INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-8940392-B2 | Titanium based inorganic-organic hybrid solid material, method for preparing same and uses thereof | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2015-01-27 | — | — | US | disclosed |
| US-20120121904-A1 | TITANIUM BASED INORGANIC-ORGANIC HYBRID SOLID MATERIAL, METHOD FOR PREPARING SAME AND USES THEREOF | L'UNIVERSITE PIERRE ET MARIE CURIE, (PARIS 6) (FR) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142889-A1 | TOPICAL COMPOSITION | CUTA, TYR, ERCC4 | TSHR 3821/4885CASP1 3745/4885SMN1; SMN2 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.